Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00646555 · ClinicalTrials.gov registry record
Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 300
- Enrollment target
NCT00646555: Completed study, sponsored by National Cancer Institute (NCI).
NCT00646555 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00646555 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
This study, conducted by the NCI and the George Washington University Medical Center (GWUMC), will examine breast tissue from patients with inflammatory breast cancer (IBC) for tumor markers and factors associated with angiogenesis. Angiogenesis is the formation of new blood vessels that is essential for tumor growth and spread. IBC is an extremely rare, aggressive form of breast cancer that disproportionately affects young women. The risk factors for IBC, its cause, and how it develops are unknown, but the disease appears to involve a high degree of angiogenesis. Tissue specimens for this study will be obtained from GWUMC's Inflammatory Breast Cancer Registry and Biospecimen Repository. The registry was established to develop a national registry of patients with IBC that includes standardized clinical, epidemiological, and pathological information, along with disease recurrence and survival data. For this study, tissue specimens from the repository will be tested for biological markers and angiogenesis parameters to help in the classification of the tumors. Biological markers (such as estrogen receptor, progesterone receptor, the p53 gene, and others) and angiogenesis parameters (such as various proteins involved in vessel formation) will be examined to determine their prevalence in tissue specimens and their relationship to patient survival. When possible, the findings will be compared with non-IBC tissue samples.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2003-11-20 |
| Est. Completion | 2012-04-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00646555
The ClinicalTrials.gov registry entry for NCT00646555 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00646555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00646555 about?
NCT00646555 is a clinical study titled "Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis". This study, conducted by the NCI and the George Washington University Medical Center (GWUMC), will examine breast tissue from patients with inflammatory breast cancer (IBC) for tumor markers and factors associated with angiogenesis. Angiogenesis is the formation of new blood vessels that is essentia...
What is the current status of trial NCT00646555?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2003-11-20. Estimated completion is 2012-04-10.
Who is sponsoring clinical trial NCT00646555?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.